Search Results | Blood | American Society of Hematology

1-20 of 350

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Blood (2020) 136 (Supplement 1): 25–26.

DOI: https://doi.org/10.1182/blood-2020-140410

Published: 2020

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Yi Lin, MD PhD, Noopur S. Raje, MD, Jesus G. Berdeja, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Michaela Liedtke, MD, Jacalyn Rosenblatt, MD, Marcela V. Maus, MD PhD, Monica Massaro, MPH, Fabio Petrocca, MD, Andrea Caia, MS, Zhihong Yang, PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Nikhil C. Munshi, MD, James N. Kochenderfer, MD

Blood (2020) 136 (Supplement 1): 26–27.

DOI: https://doi.org/10.1182/blood-2020-134324

Published: 2020

Journal Articles

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Blood (2020) 136 (Supplement 1): 39.

DOI: https://doi.org/10.1182/blood-2020-134538

Published: 2020

Journal Articles

Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial

Nina Shah, MD, Michel Delforge, Jesús F. San-Miguel, Kaitlyn B. Bertin, Muna J Tahir, Hannah B. Lewis, Julie Wang, PharmD, PhD, Julia Braverman, PhD, Timothy B. Campbell, MD PhD, Devender Dhanda, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 28–29.

DOI: https://doi.org/10.1182/blood-2020-136665

Published: 2020

Journal Articles

Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma

Chandraditya Chakraborty, PhD, Eugenio Morelli, MD, Srikanth Talluri, PhD, Sanika Derebail, MS, Yan Xu, MD, Yao Yao, María Linares, Alba Rodríguez García, Kenneth Anderson, MD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 40.

DOI: https://doi.org/10.1182/blood-2020-142178

Published: 2020

Journal Articles

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 22–25.

DOI: https://doi.org/10.1182/blood-2020-136307

Published: 2020

Journal Articles

A High Throughput Functional Screen Identifies a Novel Apex Inhibitor: Augments Cytotoxicity While Significantly Decreasing Genomic Evolution in Myeloma

Srikanth Talluri, PhD, Jialan Shi, MDPhD, Mychell Neptune-Buon, Subodh Kumar, PhD, Lakshmi B. Potluri, MBBS, Nikhil C. Munshi, MD, Masood A. Shammas, PhD

Blood (2020) 136 (Supplement 1): 10–11.

DOI: https://doi.org/10.1182/blood-2020-139945

Published: 2020

Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-141549

Published: 2020

Journal Articles

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Mehmet K. Samur, PhD, Marco Roncador, MD MSc, Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Abdul Hamid Bazarbachi, MD, Raphael Szalat, Masood A. Shammas, PhD, Adam S Sperling, MD PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Anjan Thakurta, Aurore Perrot, Jill Corre, PharmD, PhD, Philippe Moreau, MD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 4–5.

DOI: https://doi.org/10.1182/blood-2020-139014

Published: 2020

Journal Articles

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Sanika Derebail, MS, Raphael Szalat, Giovanni Parmigiani, PhD, Jill Corre, PharmD, PhD, Herve Avet-Loiseau, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 2.

DOI: https://doi.org/10.1182/blood-2020-139066

Published: 2020

Journal Articles

Exploring POU2AF1 ( BOB-1 ) D ependency and Transcription Addiction in Multiple Myeloma

Zuzana Chyra, PhD, Mehmet Kemal Samur, PhD, Anil Aktas-Samur, PhD, Yan Xu, MD, Eugenio Morelli, MD, Sophia Adamia, PhD, Woojun D Park, Lin Charles, PhD, Masood A. Shammas, PhD, Roman Hajek, MD PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 49.

DOI: https://doi.org/10.1182/blood-2020-142587

Published: 2020

Journal Articles

Atpase Family AAA Domain-Containing Protein 2 (ATAD2) As a Novel Target in Multiple Myeloma

Lakshmi B. Potluri, MBBS, Srikanth Talluri, PhD, Leutz Buon, Mehmet K. Samur, PhD, Anil Aktas-Samur, PhD, Jialan Shi, MDPhD, Chandraditya Chakraborty, PhD, Subodh Kumar, PhD, Rao Prabhala, Masood A. Shammas, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 50.

DOI: https://doi.org/10.1182/blood-2020-140466

Published: 2020

Journal Articles

Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application

Annamaria Gulla, MD, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Cirino Botta, MDPhD, Teru Hideshima, MD PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Stefano Malvestiti, MD, Rao Prabhala, Srikanth Talluri, PhD, Yu-Tzu Tai, PhD, Kenneth Wen, Paul G. Richardson, MD, Ruben D. Carrasco, MD PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 7–8.

DOI: https://doi.org/10.1182/blood-2020-140356

Published: 2020

Journal Articles

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Anil Aktas-Samur, PhD, Abdul Hamid Bazarbachi, MD, Yu-Tzu Tai, PhD, Timothy B. Campbell, MD PhD, Fabio Petrocca, MD, Kristen Hege, MD, Shari Kaiser, PhD, Kenneth Anderson, MD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 14.

DOI: https://doi.org/10.1182/blood-2020-139040

Published: 2020

Journal Articles

ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application

Subodh Kumar, PhD, Srikanth Talluri, PhD, Jiangning Zhao, PhD MD, Chengcheng Liao, PhD MD, Lakshmi B. Potluri, MBBS, Leutz Buon, Shidai Mu, Jialan Shi, MDPhD, Mychell Neptune-Buon, Chandraditya Chakraborty, PhD, Yu-Tzu Tai, PhD, Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Rao Prabhala, Masood A. Shammas, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 51.

DOI: https://doi.org/10.1182/blood-2020-142793

Published: 2020

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

DOI: https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

Chandraditya Chakraborty, PhD, Yan Xu, MD, Yao Yao, Eugenio Morelli, MD, Anil Aktas-Samur, PhD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD, Kenneth Anderson, MD, Chandraditya Chakraborty, PhD

Blood (2020) 136 (Supplement 1): 21–22.

DOI: https://doi.org/10.1182/blood-2020-142655

Published: 2020

Journal Articles

A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias

Adam S Sperling, MD PhD, Rebecca Georgakopoulou, MSc, Mehmet Kemal Samur, PhD, Christine Ivy Liacos, MSc, Brittany E Sandoval, MSc, Flora Zagouri, MD, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Despina Fotiou, BMBS, MA, Ioannis Ntanasis-Stathopoulos, MD, Evangelos Terpos, MDPhD, Efstathios Kastritis, MD, Nikhil C. Munshi, MD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 8.

DOI: https://doi.org/10.1182/blood-2020-137337

Published: 2020

Journal Articles

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Eno Inyang, PharmD, BCPS, Nikhil C. Munshi, MD, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 11.

DOI: https://doi.org/10.1182/blood-2020-136342

Published: 2020

Journal Articles

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Yao Yao, Woojun D Park, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Nicholas P Kwiatkowski, PhD, Yan Xu, MD, Chandraditya Chakraborty, PhD, Behnam Nabet, PhD, Marta Chesi, PhD, Herve Avet-Loiseau, Nathaniel Gray, Richard A. Young, PhD, Kenneth Anderson, MD, Charles Y Lin, PhD, Nikhil C. Munshi, MD, Mariateresa Fulciniti, PhD

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-142592

Published: 2020

2 3 4 5

NARROW

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial

Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

A High Throughput Functional Screen Identifies a Novel Apex Inhibitor: Augments Cytotoxicity While Significantly Decreasing Genomic Evolution in Myeloma

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Exploring POU2AF1 ( BOB-1 ) D ependency and Transcription Addiction in Multiple Myeloma

Atpase Family AAA Domain-Containing Protein 2 (ATAD2) As a Novel Target in Multiple Myeloma

Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only